Retinol deprivation partially rescues the skeletal mineralization defects of Phex-deficient Hyp mice

Bone

Volumn 53, Issue 1, 2013, Pages 231-238

  Seitz, Sebastian ^a   Rendenbach, Carsten ^a   Barvencik, Florian ^a   Streichert, Thomas ^a   Jeschke, Anke ^a   Schulze, Jochen ^a   Amling, Michael ^a   Schinke, Thorsten ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Mineralization; Osteomalacia; Phex; Retinol; X linked hypophosphatemic rickets

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; RETINOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DISEASE; BONE MATRIX; BONE MINERALIZATION DEFECT; CONTROLLED STUDY; FEMALE; FGF23 GENE; GENE EXPRESSION; GENETIC TRANSCRIPTION; GROWTH PLATE; HYPOPHOSPHATEMIA; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOID; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PHOSPHATE METABOLISM; RETINOL DEFICIENCY;

ANIMALS; BASE SEQUENCE; CALCIFICATION, PHYSIOLOGIC; DIET; DNA PRIMERS; FIBROBLAST GROWTH FACTORS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; MICE; PHEX PHOSPHATE REGULATING NEUTRAL ENDOPEPTIDASE; POLYMERASE CHAIN REACTION; VITAMIN A;

EID: 84872279354     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2012.12.009     Document Type: Article

References (61)

1. Quarles L.D., Drezner M.K. Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab 2001, 86:494-496.
2. The H.Y.P. Consortium [No authors listed]. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 1995, 11:130-136.
3. Turner A.J., Tanzawa K. Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J 1997, 11:355-364.
4. Strom T.M., Francis F., Lorenz B., Böddrich A., Econs M.J., Lehrach H., et al. Pex gene deletions in Gy and Hyp mice provide mouse models for X-linked hypophosphatemia. Hum Mol Genet 1997, 6:165-171.
5. Beck L., Soumounou Y., Martel J., Krishnamurthy G., Gauthier C., Goodyer C.G., et al. Pex/PEX tissue distribution and evidence for a deletion in the 3' region of the Pex gene in X-linked hypophosphatemic mice. J Clin Invest 1997, 99:1200-1209.
6. Strom T.M., Jüppner H. PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens 2008, 17:357-362.
7. Kumar R. Phosphatonin-a new phosphaturetic hormone? (lessons from tumour-induced osteomalacia and X-linked hypophosphataemia). Nephrol Dial Transplant 1997, 12:11-13.
8. Meyer R.A., Meyer M.H., Gray R.W. Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 1989, 4:493-500.
9. Nesbitt T., Coffman T.M., Griffiths R., Drezner M.K. Crosstransplantation of kidneys in normal and Hyp mice. Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 1992, 89:1453-1459.
10. Tenenhouse H.S., Beck L. Renal Na-phosphate cotransporter gene expression in X-linked Hyp and Gy mice. Kidney Int 1996, 49:1027-1032.
11. Du L., Desbarats M., Viel J., Glorieux F.H., Cawthorn C., Ecarot B. cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone. Genomics 1996, 36:22-28.
12. Guo R., Quarles L.D. Cloning and sequencing of human PEX from a bone cDNA library: evidence for its developmental stage-specific regulation in osteoblasts. J Bone Miner Res 1997, 12:1009-1017.
13. ADHR Consortium Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348.
14. Bergwitz C., Jüppner H. FGF23 and syndromes of abnormal renal phosphate handling. Adv Exp Med Biol 2012, 728:41-64.
15. Liu S., Zhou J., Tang W., Jiang X., Rowe D.W., Quarles L.D. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006, 291:E38-E49.
16. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun 2004, 314:409-414.
17. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., et al. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 2004, 113:561-568.
18. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T., et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
19. Benet-Pagès A., Lorenz-Depiereux B., Zischka H., White K.E., Econs M.J., Strom T.M. FGF23 is processed by proprotein convertases but not by PHEX. Bone 2004, 35:455-462.
20. Guo R., Liu S., Spurney R.F., Quarles L.D. Analysis of recombinant Phex: an endopeptidase in search of a substrate. Am J Physiol Endocrinol Metab 2001, 281:E837-E847.
21. Liu S., Guo R., Simpson L.G., Xiao Z.S., Burnham C.E., Quarles L.D. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 2003, 278:37419-37426.
22. Liu S., Tang W., Fang J., Ren J., Li H., Xiao Z., et al. Novel regulators of Fgf23 expression and mineralization in Hyp bone. Mol Endocrinol Sep 2009, 23(9):1505-1518.
23. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Defective bone formation by Hyp mouse bone cells transplanted into normal mice: evidence in favor of an intrinsic osteoblast defect. J Bone Miner Res 1992, 7:215-220.
24. Xiao Z.S., Crenshaw M., Guo R., Nesbitt T., Drezner M.K., Quarles L.D. Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol 1998, 275:E700-E708.
25. Albers J., Schulze J., Beil F.T., Gebauer M., Baranowsky A., Keller J., et al. Control of bone formation by the serpentine receptor Frizzled-9. J Cell Biol Mar 21 2011, 192(6):1057-1072.
26. McLeod M.J. Differential staining of cartilage and bone in whole mouse fetuses by alcian blue and alizarin red S. Teratology 1980, 22:299-301.
27. Amling M., Priemel M., Holzmann T., Chapin K., Rueger J.M., Baron R., et al. Rescue of the skeletal phenotype of vitamin D receptor-ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analyses. Endocrinology 1999, 140:4982-4987.
28. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
29. Kato K., Jeanneau C., Tarp M.A., Benet-Pagès A., Lorenz-Depiereux B., Bennett E.P., et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 2006, 281:18370-18377.
30. Liu S., Brown T.A., Zhou J., Xiao Z.S., Awad H., Guilak F., et al. Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 2005, 16:1645-1653.
31. Martin A., David V., Laurence J.S., Schwarz P.M., Lafer E.M., Hedge A.M., et al. Degradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYP. Endocrinology 2008, 149:1757-1772.
32. Cohen A.J., Lassová L., Golden E.B., Niu Z., Adams S.L. Retinoids directly activate the collagen X promoter in prehypertrophic chondrocytes through a distal retinoic acid response element. J Cell Biochem 2006, 99:269-278.
33. Niederreither K., Dollé P. Retinoic acid in development: towards an integrated view. Nat Rev Genet 2008, 9:541-553.
34. Nomura J., Horie I., Seto M., Nagai K., Hisatsune A., Miyata T., et al. All-trans retinoic acid increases expression of aquaporin-5 and plasma membrane water permeability via transactivation of Sp1 in mouse lung epithelial cells. Biochem Biophys Res Commun 2006, 351:1048-1053.
35. Orimo H., Shimada T. Regulation of the human tissue-nonspecific alkaline phosphatase gene expression by all-trans-retinoic acid in SaOS-2 osteosarcoma cell line. Bone 2005, 36:866-876.
36. Schinke T., Gebauer M., Schilling A.F., Lamprianou S., Priemel M., Mueldner C., et al. The protein tyrosine phosphatase Rptpzeta is expressed in differentiated osteoblasts and affects bone formation in mice. Bone 2008, 42:524-534.
37. Feskanich D., Singh V., Willett W.C., Colditz G.A. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002, 287:47-54.
38. Hough S., Avioli L.V., Muir H., Gelderblom D., Jenkins G., Kurasi H., et al. Effects of hypervitaminosis A on the bone and mineral metabolism of the rat. Endocrinology 1988, 122:2933-2939.
39. Michaëlsson K., Lithell H., Vessby B., Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003, 348:287-294.
40. Murshed M., Harmey D., Millán J.L., McKee M.D., Karsenty G. Unique coexpression in osteoblasts of broadly expressed genes accounts for the spatial restriction of ECM mineralization to bone. Genes Dev 2005, 19:1093-1104.
41. Eicher E.M., Southard J.L., Scriver C.R., Glorieux F.H. Hypophosphatemia: mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 1976, 73:4667-4671.
42. Hayashibara T., Hiraga T., Sugita A., Wang L., Hata K., Ooshima T., et al. Regulation of osteoclast differentiation and function by phosphate: potential role of osteoclasts in the skeletal abnormalities in hypophosphatemic conditions. J Bone Miner Res 2007, 22:1743-1751.
43. Ecarot B., Glorieux F.H., Desbarats M., Travers R., Labelle L. Effect of dietary phosphate deprivation and supplementation of recipient mice on bone formation by transplanted cells from normal and X-linked hypophosphatemic mice. J Bone Miner Res 1992, 7:523-530.
44. Liu S., Tang W., Zhou J., Vierthaler L., Quarles L.D. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice. Am J Physiol Endocrinol Metab 2007, 293:E1636-E1644.
45. Carpenter T.O., Moltz K.C., Ellis B., Andreoli M., McCarthy T.L., Centrella M., et al. Osteocalcin production in primary osteoblast cultures derived from normal and Hyp mice. Endocrinology 1998, 139:35-43.
46. Sitara D., Razzaque M.S., Hesse M., Yoganathan S., Taguchi T., Erben R.G., et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 2004, 23:421-432.
47. Yuan Q., Sato T., Densmore M., Saito H., Schüler C., Erben R.G., et al. Deletion of PTH rescues skeletal abnormalities and high osteopontin levels in Klotho-/- mice. PLoS Genet 2012, 8:e1002726.
48. Brownstein C.A., Zhang J., Stillman A., Ellis B., Troiano N., Adams D.J., et al. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse. Endocrinology 2010, 151:492-501.
49. Erben R.G., Mayer D., Weber K., Jonsson K., Jüppner H., Lanske B. Overexpression of human PHEX under the human beta-actin promoter does not fully rescue the Hyp mouse phenotype. J Bone Miner Res 2005, 20:1149-1160.
50. Bai X., Miao D., Panda D., Grady S., McKee M.D., Goltzman D., et al. Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 2002, 16:2913-2925.
51. Beck L., Karaplis A.C., Amizuka N., Hewson A.S., Ozawa H., Tenenhouse H.S. Targeted inactivation of Npt2 in mice leads to severe renal phosphate wasting, hypercalciuria, and skeletal abnormalities. Proc Natl Acad Sci U S A 1998, 95:5372-5377.
52. Arias J.L., Nakamura O., Fernández M.S., Wu J.J., Knigge P., Eyre D.R., et al. Role of type X collagen on experimental mineralization of eggshell membranes. Connect Tissue Res 1997, 36(1):21-33.
53. Seitz S., Barvencik F., Gebauer M., Albers J., Schulze J., Streichert T., et al. Preproenkephalin (Penk) is expressed in differentiated osteoblasts, and its deletion in Hyp mice partially rescues their bone mineralization defect. Calcif Tissue Int 2010, 86:282-293.
54. Barros NM, Hoac B, Neves RL, AddisonWN, Assis DM, Murshed M, et al. Proteolytic processing of osteopontin by PHEX and accumulation of osteopontin fragments in Hyp mouse bone, the murine model of X-linked hypophosphatemia. J Bone Miner Res in press [Electronic publication ahead of print].
55. Harrell R.M., Lyles K.W., Harrelson J.M., Friedman N.E., Drezner M.K. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest 1985, 75:1858-1868.
56. Ariceta G., Langman C.B. Growth in X-linked hypophosphatemic rickets. Eur J Pediatr 2007, 166:303-309.
57. Stickler G.B., Morgenstern B.Z. Hypophosphataemic rickets: final height and clinical symptoms in adults. Lancet 1989, 14:902-905.
58. Verge C.F., Lam A., Simpson J.M., Cowell C.T., Howard N.J., Silink M. Effects of therapy in X-linked hypophosphatemic rickets. N Engl J Med 1991, 325:1843-1848.
59. Rivkees S.A., El-Hajj-Fuleihan G., Brown E.M., Crawford J.D. Tertiary hyperparathyroidism during high phosphate therapy of familial hypophosphatemic rickets. J Clin Endocrinol Metab 1992, 75:1514-1518.
60. Imel E.A., DiMeglio L.A., Hui S.L., Carpenter T.O., Econs M.J. Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab 2010, 95:1846-1850.
61. Bergwitz C., Jüppner H. Disorders of phosphate homeostasis and tissue mineralisation. Endocr Dev 2009, 16:133-156.